PolyNovo Limited (ASX:PNV): Wound Care Sales, FY26 Results and Manufacturing Plans

Aditi Sarkar

21 October 2026 03:23 PM AEDT

PolyNovo Limited (ASX:PNV): Wound Care Sales, FY26 Results and Manufacturing Plans

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

PolyNovo Limited (ASX:PNV) reported FY26 total revenue of AUD 150.0 million, up 16.1%.
Commercial product sales increased 16.7% to AUD 138.4 million in FY26.
FY26 EBITDA was AUD 12.1 million, while net profit after tax was AUD 7.3 million.
Operating cash inflow reached AUD 23.1 million; a new manufacturing facility moved into validation.

PolyNovo Limited (ASX:PNV) develops synthetic, biodegradable medical devices designed to support tissue regeneration in burns, traumatic injuries and complex surgical wounds. Its NovoSorb platform underpins two commercial wound matrices, while its recent FY26 disclosures detail expanded product sales, operating cash generation and preparations for additional manufacturing capacity. For the 20 October 2026 trading session, the shares were reported at a closing price of AUD 0.908, an increase of 0.28% for the day. The price movement is not attributed to the company’s earlier announcements.

Company Business

Melbourne-based PolyNovo operates in the medical device industry, commercialising products manufactured from its proprietary NovoSorb polymer technology. NovoSorb BTM is a bilayer matrix with a temporary sealing membrane, intended to support dermal tissue formation before subsequent wound closure. NovoSorb MTX is a monolayer matrix developed for complex wounds where a sealing membrane is not required. The company sells into the Americas, Europe, the Middle East, Africa and Asia-Pacific, with its own operations and distribution partners across markets.

PolyNovo Limited (ASX:PNV) derives most commercial sales from its wound care products. Its FY26 annual report identifies the United States as its largest individual market, while the business also supplies markets including Australia, the United Kingdom, India and Singapore. Product registrations, clinical evidence and local reimbursement arrangements influence the pace at which devices can be made available to clinicians.

Recent Development

In August 2026, PolyNovo released its results for the financial year ended 30 June 2026. The company reported progress with its NovoSorb MTX rollout and said manufacturing output increased during the second half. Construction of a new manufacturing facility was completed, with validation activities under way ahead of a planned transition during FY27. Validation remains a necessary step before new capacity can support routine production.

PolyNovo Limited (ASX:PNV) also reported advancement of activities related to a planned US Food and Drug Administration premarket approval submission for NovoSorb BTM in full-thickness burns. That process is separate from existing uses and clearances. The company cited further clinical evidence development, including milestones under its BARDA-supported programme, as part of its regulatory work.

Financial Performance and Sector Context

FY26 total revenue, including interest and other income, reached AUD 150.0 million, compared with AUD 129.2 million in FY25. Commercial sales rose to AUD 138.4 million from AUD 118.6 million. Americas sales were AUD 104.1 million, EMEA sales AUD 20.6 million and Asia-Pacific sales AUD 13.7 million. Foreign exchange movements affected reported regional growth, making constant-currency comparisons relevant.

PolyNovo Limited (ASX:PNV) recorded EBITDA of AUD 12.1 million, up 8.1%, and net profit after tax of AUD 7.3 million, down from AUD 13.2 million. The preceding financial year included a tax benefit, whereas FY26 included a tax expense. Reported gross margin declined to 89.0% from 95.6%, with the company pointing to inventory movements. These comparisons underline the distinction between revenue expansion and statutory profitability.

Operating cash flow was AUD 23.1 million, compared with AUD 3.1 million in FY25, while free cash flow was AUD 9.4 million. Cash and cash equivalents stood at AUD 35.4 million at 30 June 2026. The company also reported insurance proceeds connected to a fire at its research and development facility; such items warrant separate consideration when comparing recurring operating results.

Risks to Consider

For PolyNovo Limited (ASX:PNV), risks include manufacturing validation and transfer delays, quality assurance requirements, clinical evidence generation and regulatory review. Medical device sales depend on hospital purchasing practices, clinician adoption and reimbursement arrangements that differ across jurisdictions. Currency fluctuations can affect translated revenue. Additional capacity also carries execution and working-capital requirements, while profitability may be influenced by production costs and the timing of development expenditure.

What to Watch Next

During FY27, the company plans to progress the transition to its new manufacturing facility and continue developing regulatory submissions, including work concerning full-thickness burns in the United States. Subsequent disclosures may provide information about capacity utilisation, NovoSorb MTX sales, regional commercial trends and operating cash conversion. Publication of trading updates and financial results will provide further evidence of the relationship between revenue, expenses and cash generation.

Key Insights

PolyNovo Limited (ASX:PNV) entered FY27 following higher FY26 commercial sales, positive statutory earnings and increased operating cash inflow. Its immediate operational agenda combines manufacturing validation, further medical-device evidence and commercial distribution of its existing wound matrices. Profit margins, market-specific regulatory progress and the cash costs of expanding operations remain relevant measures for tracking the business.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.